Loading…
Loading…
STAAR Surgical Company shares fell sharply after preliminary Q2 2026 sales met expectations but lacked forward guidance, raising investor concerns. STAA demonstrated robust revenue growth, especially in China and the Americas, with improved margins and cost discipline, but EMEA sales lagged due to geopolitical issues. Despite recent profitability and a strong cash position, uncertainty remains over the sustainability of these improvements and the absence of detailed guidance.
STAAR Surgical Company (NASDAQ:STAA) stock is trading lower on Friday after reporting preliminary net sales for the second quarter of over $90 million, compared to net sales of $44.3 million a year ago.
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced strong preliminary net sales for the second quarter ended July 3, 2026. STAAR is announcing its preliminary net sales in advance of its quarterly earnings announcement, which it expects to issue on August 12, 2026.Net sales for the second quarter of 2026 are expected to be in excess of.
STAAR Surgical supplies implantable lenses for vision correction, serving ophthalmic surgeons and clinics globally with proprietary tech.
On May 28, 2026, Staar Surgical Co (STAA) shares fell 7.3% to a current price of $29.08. This decline comes amidst a volatile trading period, as the stock has e
STAAR Surgical Company (STAA) Discusses Differentiation of EVO ICL Technology and Market Trends in Refractive Surgery Transcript
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that management will participate in the following upcoming conferences: Stifel 2026 Virtual Ophthalmology Forum Date: Tuesday, May 26, 2026 Format: Meetings and Webcast Fireside Chat Details: Investor meeting participation is by invitation only from the sponsoring brokerage firm. Webcas.
STAAR Surgical Company delivered a robust 1Q26 beat, with revenue up 119% YoY to $93.5M and a swing to $5.2M net income. China's market rebound, normalized inventory, and rapid EVO+ ICL adoption drove topline strength, while disciplined OpEx and manufacturing efficiency boosted margins to 73.6%. STAA is benefiting from a structural shift toward lens-based refractive surgery, gaining U.S. share despite a shrinking laser market and expanding its addressable market via FDA approval.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for STAA and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.